Gradalis Moves shRNA Drug into Clinic, Plans Follow-on Trial for Later in the Year

The ongoing trial is expected to help lay the groundwork for a follow-on cancer therapy that will also incorporate the company's novel RNAi approach, and is expected to enter phase I testing around the third quarter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.